penpulimab,pembrolizumab,nivolumab
akesobio,sino biopharmaceuticals,merck,bms
['pembro', 'nivo']
 if their cost is less as compared to pembrolizumab and nivo , then they can be considered as an option for lmic patients, where acesss to pembrolizumab and nivo is very less
Oncology care , to give or not to give chemo , data analysis , oncology pharamocovigilance , enthusiastic critic, twitts are not twists